March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • ACR Highlights Imaging Payment Changes in HOPPS Final Rule

    ACR outlines key radiology updates in CMS 2026 HOPPS final rule, including payment changes and quality reporting updates effective Jan. 1.

    Read more
  • ACR Provides Input to FDA on AI Measurement and Evaluation

    ACR submitted comments to FDA on real-world AI device performance, stressing safety, governance, and continuous monitoring.

    Read more
  • Radiology’s Fight Against Prior Authorization Delays

    ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.

    Read more